The utility of platelet activation biomarkers in thrombotic microangiopathies

References

• George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371(7):654–666. doi:10.1056/NEJMra1312353.
   PubMed Web of Science ®Google Scholar
• Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol 2008;23(10):1761–1767. doi:10.1007/s00467-007-0616-x.
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347(8):589–600. doi:10.1056/NEJMra020528.
   PubMed Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 2019;12(6):383–395. doi:10.1080/17474086.2019.1611423.
   PubMed Web of Science ®Google Scholar
• Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology,diagnosis, and management. J Clin Med 2021;10(3):536. doi:10.3390/jcm10030536.
   PubMed Web of Science ®Google Scholar
• Gómez-De León A, Villela-Martínez LM, Yáñez-Reyes JM, Gómez-Almaguer D. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. Expert Rev Hematol 2020;13(5):461–470. doi:10.1080/17474086.2020.1750361.
   PubMed Web of Science ®Google Scholar
• Gresele P, Bury L, Mezzasoma AM, Falcinelli E. Platelet function assays in diagnosis: an update. Expert Rev Hematol 2019;12(1):29–46. doi:10.1080/17474086.2019.1562333.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Völker U, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021;138(22):2256–2268. doi:10.1182/blood.2021013231.
   PubMed Web of Science ®Google Scholar
• Handtke S, Wolff M, Zaninetti C, Wesche J, Schönborn L, Aurich K, Ulm L, Hübner NO, Becker K, Thiele T, et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood 2021;137(26):3656–3659. doi:10.1182/blood.2021012064.
   PubMed Web of Science ®Google Scholar
• Yun SH, Sim EH, Goh RY, Park JI, Han JY. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int 2016;e:9060143.
   Google Scholar
• Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20(3):143–149. doi:10.1080/09537100802710286.
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med 2019;381(17):1653–1662. doi:10.1056/NEJMra1813013.
   PubMed Web of Science ®Google Scholar
• Rubenstein MD, Wall RT. Clinical use of beta-thromboglobulin levels in diagnosing and treating consumptive and immune thrombocytopenia. Am J Hematol 1981;10(4):369–373. doi:10.1002/ajh.2830100406.
   PubMed Web of Science ®Google Scholar
• Widemann A, Pasero C, Arnaud L, Poullin P, Loundou AD, Choukroun G, Sanderson F, Lacroix R, Sabatier F, Coppo P, ENDO-13 study group, et al. Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study. J Thromb Haemost 2014;12(10):1601–1609. doi:10.1111/jth.12681.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Suzuki K, Mastumoto T, Ikejiri M, Ohishi K, Katayama N, Suzuki-Inoue K, Wada H. Elevated plasma levels of soluble C-type lectin-like receptor 2 (CLEC2) in patients with thrombotic microangiopathy. Thromb Res 2019;178:54–58. doi:10.1016/j.thromres.2019.03.018.
   PubMed Web of Science ®Google Scholar
• May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009;114(16):3464–3472. doi:10.1182/blood-2009-05-222273.
   PubMed Web of Science ®Google Scholar
• Karpman D, Manea M, Vaziri-Sani F, Ståhl AL, Kristoffersson AC. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006;32(2):128–145. doi:10.1055/s-2006-939769.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17(8):543–553. doi:10.1038/s41581-021-00424-4.
   PubMed Web of Science ®Google Scholar
• Tiwari NR, Phatak S, Sharma VR, Agarwal SK. COVID-19 and thrombotic microangiopathies. Thromb Res 2021;202:191–198. doi:10.1016/j.thromres.2021.04.012.
   PubMed Web of Science ®Google Scholar
• Timmermans SAMEG, van Paassen P. The syndromes of thrombotic microangiopathy: a critical appraisal on complement dysregulation. J Clin Med 2021;10(14):3034. doi:10.3390/jcm10143034.
   PubMed Web of Science ®Google Scholar
• Castro P, Palomo M, Moreno-Castaño AB, Fernández S, Torramadé-Moix S, Pascual G, Martinez-Sanchez J, Richardson E, Téllez A, Nicolas JM, et al. Is the endothelium the missing link in the pathophysiology and treatment of COVID-19 complications? Cardiovasc Drugs Ther 2021;1–14. doi:10.1007/s10557-020-07069-8.
   PubMedGoogle Scholar
• de Bruijn S, Maes MB, De Waele L, Vanhoorelbeke K, Gadisseur A. First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost 2021;19(8):2014–2018. doi:10.1111/jth.15418.
   PubMed Web of Science ®Google Scholar
• Zheng XL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost 2021;19(8):1864–1871. doi:10.1111/jth.15406.
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Arthur JF, Shen Y, Karunakaran D, Moore LA, Am Esch JS 2nd, Andrews RK, Berndt MC. GPIbalpha-selective activation of platelets induces platelet signaling events comparable to GPVI activation events. Platelets 2010;21(4):244–252. doi:10.3109/09537101003695339.
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Andrews RK. Structure and function of platelet receptors initiating blood clotting. Adv Exp Med Biol 2014;844:263–275.
   PubMed Web of Science ®Google Scholar
• Qiao J, Wu X, Luo Q, Wei G, Xu M, Wu Y, Liu Y, Li X, Zi J, Ju W, et al. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis. Haematologica 2018;103(9):1568–1576. doi:10.3324/haematol.2018.191700.
   PubMed Web of Science ®Google Scholar
• Matevosyan K, Sarode R. Thrombosis, microangiopathies, and inflammation. Semin Thromb Hemost 2015;41(6):556–562. doi:10.1055/s-0035-1556587.
   PubMed Web of Science ®Google Scholar
• Smith BR, Rinder HM. Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura. Semin Hematol 1997;34(2):90–97.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, TITAN Investigators, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374(6):511–522. doi:10.1056/NEJMoa1505533.
   PubMed Web of Science ®Google Scholar
• Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 2021;137(6):733–742. doi:10.1182/blood.2020008021.
   PubMedGoogle Scholar
• Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Davì G. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost 2012;108(6):1109–1123. doi:10.1160/TH12-08-0550.
   PubMed Web of Science ®Google Scholar
• Tahmasbi L, Karimi M, Kafiabadi SA, Nikougoftar M, Haghpanah S, Ranjbaran R, Moghadam M. Evaluation of plasma platelet microparticles in thrombotic thrombocytopenic purpura. Ann Clin Lab Sci 2017;47(1):62–67.
   PubMed Web of Science ®Google Scholar
• Katayama M, Handa M, Araki Y, Ambo H, Kawai Y, Watanabe K, Ikeda Y. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993;84(4):702–710. doi:10.1111/j.1365-2141.1993.tb03149.x.
   PubMed Web of Science ®Google Scholar
• Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994;83(6):1535–1541. doi:10.1182/blood.V83.6.1535.1535.
   PubMed Web of Science ®Google Scholar
• Vianelli N, Catani L, Gugliotta L, Nocentini F, Baravelli S, Lancellotti G, Tura S. Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura. Haematologica 1996;81(1):3–7.
   PubMed Web of Science ®Google Scholar
• Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77(6):1081–1085. doi:10.1055/s-0038-1656116.
   PubMed Web of Science ®Google Scholar
• Yngen M, Östenson CG, Hu H, Li N, Hjemdahl P, Wallén NH. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004;47(3):537–540. doi:10.1007/s00125-004-1352-4.
   PubMed Web of Science ®Google Scholar
• van den Born BJ, Löwenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, van Montfrans GA. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 2011;29(5):922–927. doi:10.1097/HJH.0b013e328345023d.
   PubMed Web of Science ®Google Scholar
• Abrey Recalde MJ, Alvarez RS, Alberto F, Mejias MP, Ramos MV, Fernandez Brando RJ, Bruballa AC, Exeni RA, Alconcher L, Ibarra CA, et al. Soluble CD40 ligand and oxidative response are reciprocally stimulated during Shiga toxin-associated hemolytic uremic syndrome. Toxins (Basel) 2017;9(11):331. doi:10.3390/toxins9110331.
   Web of Science ®Google Scholar
• Galicia López A, Olguín Ortega L, Saavedra MA, Méndez Cruz R, Jimenez Flores R, García de La Peña M. Increased concentrations of soluble CD40 ligand platelet in patients with primary antiphospholipidic syndrome. Reumatol Clin 2013;9(4):216–220. doi:10.1016/j.reuma.2012.10.018.
   PubMedGoogle Scholar
• Nomura S, Ishii K, Kanazawa S, Inami N, Uoshima N, Ishida H, Yoshihara T, Kitayama H, Hayashi K. Significance of elevation in cell-derived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant 2005;36(10):921–922. doi:10.1038/sj.bmt.1705150.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Naitoh K, Wada H, Ikejiri M, Mastumoto T, Ohishi K, Hosaka Y, Nishikawa M, Katayama N. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb Res 2014;133(3):440–444. doi:10.1016/j.thromres.2013.11.023.
   PubMed Web of Science ®Google Scholar
• Fong JS, Kaplan BS. Impairment of platelet aggregation in hemolytic uremic syndrome: evidence for platelet “exhaustion.” Blood 1982;60(3):564–570. doi:10.1182/blood.V60.3.564.564.
   PubMed Web of Science ®Google Scholar
• Alwayn IP, Buhler L, Appel JZ 3rd, Goepfert C, Csizmadia E, Correa L, Harper D, Kitamura H, Down J, Awwad M, et al. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation 2001;71(11):1601–1609. doi:10.1097/00007890-200106150-00020.
   PubMed Web of Science ®Google Scholar
• Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011;187(1):172–180. doi:10.4049/jimmunol.1100491.
   PubMed Web of Science ®Google Scholar
• Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A, Zoja C, Remuzzi G. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001;98(6):1828–1835. doi:10.1182/blood.V98.6.1828.
   PubMed Web of Science ®Google Scholar
• Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005;93(3):443–452. doi:10.1160/TH04-07-0450.
   PubMed Web of Science ®Google Scholar
• Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Kongkhum S, Heatherly D, Obrig T, Gear AR. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect Immun 2005;73(12):8306–8316. doi:10.1128/IAI.73.12.8306-8316.2005.
   PubMed Web of Science ®Google Scholar
• Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013;122(2):282–292. doi:10.1182/blood-2013-03-489245.
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Svensson M, Mörgelin M, Svanborg C, Tarr PI, Mooney JC, Watkins SL, Johnson R, Karpman D. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006;108(1):167–176. doi:10.1182/blood-2005-08-3219.
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008;111(11):5307–5315. doi:10.1182/blood-2007-08-106153.
   PubMed Web of Science ®Google Scholar
• Wright JF, Wang H, Hornstein A, Hogarth M, Mody M, Garvey MB, Blanchette V, Rock G, Freedman J. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999;107(3):546–555. doi:10.1046/j.1365-2141.1999.01751.x.
   PubMed Web of Science ®Google Scholar
• Knosalla C, Yazawa K, Behdad A, Bodyak N, Shang H, Bühler L, Houser S, Gollackner B, Griesemer A, Schmitt-Knosalla I, et al. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009;9(5):1006–1016. doi:10.1111/j.1600-6143.2009.02602.x.
   PubMed Web of Science ®Google Scholar
• Neumeister P, Hiller E, Gawaz M, Holler E, Kolb HJ, Sill H, Pihusch R, Mempel W, Wittmann G, Salat C. Changes in platelet membrane glycoproteins before bone marrow transplantation and after engraftment–a pilot study. Eur J Med Res 1998;3(10):465–469.
   PubMedGoogle Scholar
• Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996;75(3):427–431. doi:10.1055/s-0038-1650291.
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Arvidsson I, Johansson KE, Chromek M, Rebetz J, Loos S, Kristoffersson AC, Békássy ZD, Mörgelin M, Karpman D. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog 2015;11(2):e1004619. doi:10.1371/journal.ppat.1004619.
   PubMed Web of Science ®Google Scholar
• Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, Ahn YS. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 2004;114(2):143–148. doi:10.1016/j.thromres.2004.06.005.
   PubMed Web of Science ®Google Scholar
• Rubinstein J, Lane A, Luebbering N, Abdullah S, Dandoy CE, Davies SM. CD40 ligand levels in pediatric cohorts correlate with baseline platelet count and transplant-associated mortality but not with endothelial injury. Biol Blood Marrow Transplant 2019;25(3):S133–S134. doi:10.1016/j.bbmt.2018.12.420.
   Web of Science ®Google Scholar
• Montague SJ, Andrews RK, Gardiner EE. Mechanisms of receptor shedding in platelets. Blood 2018;132(24):2535–2545. doi:10.1182/blood-2018-03-742668.
   PubMed Web of Science ®Google Scholar
• Kunishima S, Kobayashi S, Naoe T. Increased but highly dispersed levels of plasma glycocalicin in patients with disseminated intravascular coagulation. Eur J Haematol 1996 Mar;56(3):173–177. doi:10.1111/j.1600-0609.1996.tb01338.x.
   PubMed Web of Science ®Google Scholar
• Murphy WG, Moore JC, Kelton JG. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura. Blood 1987;70(5):1683–1687. doi:10.1182/blood.V70.5.1683.1683.
   PubMed Web of Science ®Google Scholar
• Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug Des Devel Ther 2019;13:1251–1258. doi:10.2147/DDDT.S134470.
   PubMed Web of Science ®Google Scholar
• Cheng H, Yan R, Li S, Yuan Y, Liu J, Ruan C, Dai K. Shear-induced interaction of platelets with von Willebrand factor results in glycoprotein Ibalpha shedding. Am J Physiol Heart Circ Physiol 2009;297(6):H2128–35. doi:10.1152/ajpheart.00107.2009.
   PubMed Web of Science ®Google Scholar
• Gitz E, Pollitt AY, Gitz-Francois JJ, Alshehri O, Mori J, Montague S, Nash GB, Douglas MR, Gardiner EE, Andrews RK, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014;124(14):2262–2270. doi:10.1182/blood-2014-05-572818.
   PubMed Web of Science ®Google Scholar
• Inoue O, Osada M, Nakamura J, Kazama F, Shirai T, Tsukiji N, Sasaki T, Yokomichi H, Dohi T, Kaneko M, et al. Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI. Int J Hematol 2019;110(3):285–294. doi:10.1007/s12185-019-02680-4.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Wada H, Ichkawa Y, Tanaka M, Tashiro H, Shiraki K, Shimpo H, Yamashita Y, Mastumoto T, Shimaoka M, et al. Soluble C-type lectin-like receptor 2 is a biomarker for disseminated intravascular coagulation. J Clin Med 2021;10(13):2860. doi:10.3390/jcm10132860.
   PubMed Web of Science ®Google Scholar
• Nazy I, Elliott TD, Arnold DM. Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor. Br J Haematol 2020;190:594–598. doi:10.1111/bjh.16553.
   PubMed Web of Science ®Google Scholar
• McRoyan DK, Daniel SJ, Liu PI. Beta-Thromboglobulin and platelet factor 4 levels in a case of acute thrombotic thrombocytopenic purpura. South Med J 1985;78(6):745–748. doi:10.1097/00007611-198506000-00034.
   PubMed Web of Science ®Google Scholar
• Arepally GM, Cines DB. Pathogenesis of heparin-induced thrombocytopenia. Transl Res 2020;225:131–140. doi:10.1016/j.trsl.2020.04.014.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, Aurich K, Lalk M, Methling K, Volker U, et al. Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Blood 2021;blood.2021013231. doi:10.1182/blood.2021013231.
   Google Scholar
• Appiani AC, Edefonti A, Bettinelli A, Cossu MM, Paracchini ML, Rossi E. The relationship between plasma levels of the factor VIII complex and platelet release products (beta-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome. Clin Nephrol 1982;17(4):195–199.
   PubMed Web of Science ®Google Scholar
• Han P, Turpie AG, Genton E. Plasma beta-thromboglobulin: differentiation between intravascular and extravascular platelet destruction. Blood 1979;54(5):1192–1196. doi:10.1182/blood.V54.5.1192.1192.
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Sartz L, Nelsson A, Békássy ZD, Karpman D. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 2009;4(9):e6990. doi:10.1371/journal.pone.0006990.
   PubMed Web of Science ®Google Scholar
• Jy W, Horstman LL, Park H, Mao WW, Valant P, Ahn YS. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998;57(1):33–42. doi:10.1002/(SICI)1096-8652(199801)57:1<33::AID-AJH6>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011;117(20):5503–5513. doi:10.1182/blood-2010-09-309161.
   PubMed Web of Science ®Google Scholar
• Ahn YS, Jy W, Kolodny L, Horstman LL, Mao WW, Valant PA, Duncan RC. Activated platelet aggregates in thrombotic thromboctyopenic purpura: decrease with plasma infusions and normalization in remission. Br J Haematol 1996;95(2):408–415. doi:10.1046/j.1365-2141.1996.d01-1902.x.
   PubMed Web of Science ®Google Scholar
• Kelton JG, Warkentin TE, Hayward CP, Murphy WG, Moore JC. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood 1992;80(9):2246–2251. doi:10.1182/blood.V80.9.2246.2246.
   PubMed Web of Science ®Google Scholar
• Wang HX, Han B, Zhao YY, Kou L, Guo LL, Sun TW, Song LJ. Serum D-dimer as a potential new biomarker for prognosis in patients with thrombotic thrombocytopenic purpura. Medicine (Baltimore) 2020;99(13):e19563. doi:10.1097/MD.0000000000019563.
   PubMed Web of Science ®Google Scholar
• Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, Matsumoto M, Fujimura Y, Yatomi Y, Nangaku M. Profiles of coagulation and fibrinolysis activation-associated molecular markers of atypical hemolytic uremic syndrome in the acute phase. J Atheroscler Thromb 2020;27(4):353–362. doi:10.5551/jat.49494.
   PubMed Web of Science ®Google Scholar
• Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, Maharjan A, Gautam R. D-dimer as a biomarker for assessment of COVID-19 prognosis: d-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One 2021;16(8):e0256744. doi:10.1371/journal.pone.0256744.
   PubMed Web of Science ®Google Scholar
• Erickson YO, Samia NI, Bedell B, Friedman KD, Atkinson BS, Raife TJ. Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher 2009;24(4):150–154. doi:10.1002/jca.20205.
   PubMed Web of Science ®Google Scholar